ASCO 2019

ASCO 2019 and the future of oncology
Kantar-video-image-myeloma

ASCO 2019 - Kantar reviews multiple myeloma showdown

Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen's Darzalex and Sanofi's isatuximab. Darzalex showed more positive data in newly-d